James C. Mulloy, PhD

Member, Experimental Hematology & Cancer Biology

Professor, UC Department of Pediatrics

Phone 513-636-1844

Fax 513-636-3768

Email james.mulloy@cchmc.org

BA: St. Anselm College, Manchester, NH, 1986.

MS: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1989.

PhD: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1992.

View PubMed Publications

Goyama S, Wunderlich M, Mulloy JC. Xenograft models for normal and malignant hematopoiesis. Blood. Apr 23;125(17):2630-2640, 2015.

Roychoudhury J, Clark JP, Gracia-Maldonado G, Unnisa Z, Wunderlich M, Link KA, Dasgupta N, Aronow B, Huang G, Mulloy JC, Kumar AR. MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia. Blood. Apr 16;125(16):2544-52, 2015.

Vadukoot AK, AbdulSalam SF, Wunderlich M, Pullen ED, Landero-Figueroa J, Mulloy JC, Merino EJ. Design of a hydrogen peroxide-activatable agent that specifically targets cancer cells. Bioorganic & Medicinal Chemistry. Dec 15;22(24):6885-92, 2014.

Goyama S, Huang G, Kurokawa M, Mulloy JC. Posttranslational modifications of RUNX1 as potential anticancer targets. Oncogene. Sep 29;0. doi: 10.1038/onc. 2014.

Wunderlich M, Brooks RA, Panchal R, Rhyasen GW, Danet-Desnoyers G, Mulloy JC. OKT3 antibody pre-treatment prevents xenogeneic GVHD and allows for reliable initiation of xenografts from unfractionated human hematopoietic tissues. Blood. Jun 12;123(24):e134-44, 2014.

Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, Mulloy JC, Zhang J. Combined inhibition of MEK and JAK rescues mutant hematopoietic stem cell function and provides long-term survival in NrasG12D/G12D JMML/CMML mice. Journal of Clinical Investigation. Jun 2;124(6):2762-73, 2014.

Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT. An MDS xenograft model utilizing a patient-derived cell line. Leukemia, May;28(5):1142-5, 2014.

Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G. Down-regulation of RUNX1/CBFβ by MLL fusion proteins enhances HSC self-renewal. Blood. Mar 13;123(11):1729-38, 2014.

Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. Journal of Clinical Investigation. 2014 Jan 2;124(1):222-36.

Mulloy JC. A new inducible model for t(8;21) AML. EMBO Mol Med. 2013 Dec;5(12):1795-7.

Conferring in vivo metabolic resistance to a highly selective anti-AML agent. Co-Investigator. National Institutes of Health R21 NCI (Merino/Mulloy). Apr 2014 - Mar 2016.

LSC mobilization and differentiation therapy. Co-Principal Investigator. Hyundai Hope On Wheels! (Mulloy/Mizukawa). Sep 2013 - Aug 2015.